Stock listing

TCRX Stock Price, News, Filings & Events — Tscan Therapeutics, Inc.

Selected listing: TCRX · BOATS · USD · US

This page tracks Tscan Therapeutics, Inc.'s TCRX:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following TCRX:BOATS. TCRX:BOATS is the stock-level entry point for investors researching Tscan Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Tscan Therapeutics, Inc. is a public company traded under the ticker TCRX in the American market. The company has a market capitalization of approximately $51.9 million. Tscan focuses on developing innovative therapies for cancer and other diseases through its proprietary T-cell receptor platform.

TCRX:BOATSUSDUSUpdated September 11, 2026
Tscan Therapeutics, Inc. logo
Ticker
TCRX:BOATS
Asset type
Stock
Market cap
$21.7M
Sector
Health Technology
Industry
Biotechnology
Exchange
BOATS
Currency
USD

Tscan Therapeutics, Inc. TCRX:BOATS stock context

This page tracks Tscan Therapeutics, Inc.'s TCRX:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following TCRX:BOATS. TCRX:BOATS is the stock-level entry point for investors researching Tscan Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Tscan Therapeutics, Inc. is a public company traded under the ticker TCRX in the American market. The company has a market capitalization of approximately $51.9 million. Tscan focuses on developing innovative therapies for cancer and other diseases through its proprietary T-cell receptor platform.

Latest news from Tscan Therapeutics, Inc.

All Tscan Therapeutics, Inc. news →

Research Tscan Therapeutics, Inc.

Alternate listings